Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 (programmed death-ligand 1) expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.1

PD-L1 acts to switch off immune cells that would otherwise attack the cancer cells. By attaching to PD-L1 and reducing its effects, Tecentriq increases the ability of the immune system to attack the cancer cells and thereby slow down progression of the disease.2

In Bangladesh Tecentriq is approved for the following indications.3

Tecentriq as monotherapy is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):

• after prior chemotherapy, or

• who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥ 5%, or who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.

Tecentriq as monotherapy is indicated as adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II to IIIA (7th edition of the UICC/AJCC-staging system) NSCLC whose tumors have PD-L1 expression on ≥ 1% tumor cells (TC).

• Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC). Patients with EGFR or ALK genomic tumor aberrations should have received targeted therapy if clinically indicated prior to receiving Tecentriq.

• Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for first-line treatment of patients with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations.

• Tecentriq as monotherapy is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have a PD-L1 expression ≥ 50% tumor cells (TC) or ≥ 10% tumor-infiltrating immune cells (IC) and who do not have EGFR or ALK genomic tumor aberrations.

• Tecentriq as monotherapy is indicated for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy.

Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Tecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression of ≥1% on IC, and who have not received prior chemotherapy for metastatic disease.

Tecentriq, in combination with bevacizumab, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Tecentriq, in combination with Cotellic and Zelboraf, is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Tecentriq as monotherapy is indicated for the treatment of unresectable or metastatic alveolar soft part sarcoma (ASPS) in patients 2 years of age and older.

For more disease and medicine related queries you may discuss with your physician.

In Bangladesh Tecentriq is available as Single-use vial of 60 mg/ml (20 mL vial containing a total of 1,200 mg atezolizumab)

References

1. Roche - Tecentriq (atezolizumab) [Internet; cited 2020, March 17]. Retrieved from

2. Tecentriq | European Medicines Agency [Internet; cited 2020, March 17]. Retrieved from

3. Tecentriq-Product-Information-BD-RO-554-1267-May-2023